Combination Chemotherapy with Cisplatin , Etoposide , and Ifosfamide ( PIE ) in the Advanced Non - Small Cell Lung Cancer.
- Author:
Sang Won SHIN
;
Byung Soo KIM
;
Jae Jung SHIN
;
Yeul Hong KIM
;
Kyung Ho KANG
;
Young Ho CHOI
;
Kwang Tak KIM
;
Jun Suk KIM
- Publication Type:Original Article
- Keywords:
Ifosfamide;
Cisplatin;
Etoposide;
Non-small cell lung cancer;
Chemotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Cisplatin*;
Drug Therapy;
Drug Therapy, Combination*;
Etoposide*;
Follow-Up Studies;
Humans;
Ifosfamide*;
Lung;
Mesna;
Small Cell Lung Carcinoma*;
Survival Rate
- From:Journal of the Korean Cancer Association
1998;30(2):225-230
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Combination chemotherapy with cisplatin and etoposide have been considered as one of the chemotherpy regimen for non small cell lung cacer(NSCLC) with the response rate of 20~40%. Ifosfamide is one of the most active agent against NSCLC. And so, we initiated a phase II trial for advanced NSCLC to determine the effect of PIE(cisplatin, ifosfamide, etoposide) regimen. MATERIALS AND METHODS: 36 patients with inoperable non-small cell lung cancer who had no prior systemic chemotherapy were treated with combined ifosfamide (1,800 mg/m2 plus mesna 1,100 mg/m2 by intravenous continuous infusion daily for 3 days) with cisplatin (20 mg/m2 intravenous for 3 days) and etoposide (80 mg/m2 intravenous for 3 days). We evaluated the response rate, survival and toxicities of these patients. RESULTS: The objective response rate was 28%(CR; 2/36, 6%, PR; 8/36, 22%). Among 10 responders, 7 patients were in good ECOG performance status(0~1). The mean survival of all these patients were 43 weeks(8~141 weeks); the responding patients survived longer than the non-responders(median survival; 59 weeks vs 28 weeks, p<0.05). The toxicities of this regimen were acceptable without treatment related toxic death. CONCLUSION: We concluded that PIE regimen is effective in the treatment of advanced non-small cell lung cancer with acceptable toxicities and long-term follow up is warranted.
